Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-17T18:10:50.688Z Has data issue: false hasContentIssue false
  • English
  • Français

Antidepressive effects of the selective MAO-inhibitor brofaromine:an open trial

Published online by Cambridge University Press:  16 April 2020

WMA Verhoeven
WMA Verhoeven*
Affiliation:
Vincent van Gogh Institute for Psychiatry, Department of Biological Psychiatry, Stationsweg 46, 5803, AC Venray, The Netherlands
Get access

Summary

In an open prospective study, the antidepressive effects of the selective and reversible MAO-A inhibitor, brofaromine, were investigated in nine endogenous depressed patients, who had failed to respond to cyclic antidepressants. In three patients a clinically relevant improvement was observed, although for the total group, no statistically significant treatment effect could be demonstrated. In two subjects, postural hypotension and sleep disturbances occurred temporarily.

Keywords

MAO-inhibitorbrofarominemajor depression
Type
Short communication
Information
European Psychiatry , Volume 7 , Issue 5 , 1992 , pp. 243 - 247
Copyright
Copyright © Elsevier, Paris 1992

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bech, P (1992) Newcastle Diagnostic Depression Scale 1965 In: Compendium of rating scales corresponding with DSM III, DS MIII-R and ICD-10 Syndromes (in press)Google Scholar
Bieck, PRAntonin, KH (1988) Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 8, 237–245CrossRefGoogle ScholarPubMed
Carney, MWMRoth, MGarside, RF (1965) The diagnosis of depressive syndromes and the prediction of ECT response. Br Psychiatry 111, 659–674CrossRefGoogle Scholar
Delcker, AGaertner, HJ (1991) Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor - an open study. Eur Neuropsychopharmacol 1, 177–180CrossRefGoogle ScholarPubMed
Johnston, JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17, 1285–1297CrossRefGoogle ScholarPubMed
Liebowitz, MRQuitkin, FMStewart, JWMcGrath, PJHarrison, WRabkin, JTricamo, EMarkowitz, JSKlein, DF (1984) Phenelzine vs imipramine in atypical depression. A preliminary report. Arch Gen Psychiatry 41, 669–677CrossRefGoogle Scholar
Murphy, DLCohen, RMSiever, LJRoy, BKaracan, FWyatt, RJGarrick, NALinnoila, M (1983) Clinical and laboratory studies with selective monoamine-oxidaseinhibiting drugs. Mod Prob Pharmacopsychiatry 19, 287–303CrossRefGoogle ScholarPubMed
Pare, CMB (1985) The present status of monoamine oxidase inhibitors. Br J Psychiatry 146, 576–584CrossRefGoogle ScholarPubMed
Ravaris, CLRobinson, DSYves, JONiesd, ABartlett, D (1980) Phenelzine and amitriptyline in the treatment of depression. A comparison of present and past studies. Arch Gen Psychiatry 37, 1075–1080CrossRefGoogle ScholarPubMed
Rabkin, JGQuitkin, FMPatrick, GHarrison, WTricamo, E (1985) Adverse reaction to monoamine oxidase inhibitors. Part II. Treatment correlations and clinical management. J Clin Psychopharmacol 5, 2–9CrossRefGoogle Scholar
Rohs, RGNoyes, R (1978) Agroraphobia: newer treatment approaches. J Nerv Ment Dis 166, 701–708CrossRefGoogle Scholar
Schiwy, WHeath, WRDelini-Stula, A (1989) Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dosefinding trials in depressed patients. J Neurol Trans 28, 33–44Google Scholar
Steiger, AHolsboer, FGerken, ADemisch, LBenkert, O (1987) Results of an open clinical trial of brofaromine (CGP 11305A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression. Pharmacopsychiatry 20, 262–269CrossRefGoogle Scholar
Van Vliet, IMDen Boer, JAWestenberg, HGM (1992) Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacology 2, 21–29CrossRefGoogle ScholarPubMed
Waldmeier, PCFelner, ATripton, KF (1983a) The monoamine oxidase inhibiting properties of CGP 11305A. Eur J Pharmacol 94, 73–83CrossRefGoogle Scholar
Waldmeier, PCFeldtrauer, JJStoecklin, KPaul, E (1983b) Reversibility of the interaction of CGP 11305A. Eur J Pharmacol 94, 101–108CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.